$1.07 Trillion is the total value of Casdin Capital, LLC's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SAGE | SAGE THERAPEUTICS INC | $73,236,000,000 | +115014.7% | 400,000 | 0.0% | 6.86% | -1.9% | |
MYOK | MYOKARDIA INC | $64,429,900,000 | +96341.8% | 1,285,000 | 0.0% | 6.03% | -17.8% | |
FATE | FATE THERAPEUTICS INC | $51,765,000,000 | +115436.6% | 2,550,000 | 0.0% | 4.84% | -1.5% | |
BLFS | BIOLIFE SOLUTIONS INC | $39,408,375,000 | +90604.5% | 2,428,571 | 0.0% | 3.69% | -22.7% | |
VYGR | VOYAGER THERAPEUTICS INC | $30,706,202,000 | +142117.6% | 1,128,075 | 0.0% | 2.87% | +21.2% | |
ILMN | ILLUMINA INC | $22,089,000,000 | +118396.9% | 60,000 | 0.0% | 2.07% | +1.0% | |
GNMK | GENMARK DIAGNOSTICS INC | $21,838,850,000 | +91436.8% | 3,365,000 | 0.0% | 2.04% | -22.0% | |
GBT | GLOBAL BLOOD THERAPEUTICS IN | $15,780,000,000 | +99276.5% | 300,000 | 0.0% | 1.48% | -15.3% | |
EDIT | EDITAS MEDICINE INC | $11,875,200,000 | +101086.1% | 480,000 | 0.0% | 1.11% | -13.7% | |
CDNA | CAREDX INC | $7,198,000,000 | +114081.5% | 200,000 | 0.0% | 0.67% | -2.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
CODEXIS INC | 22 | Q3 2023 | 8.1% |
SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-17 |
13F-HR | 2024-05-15 |
4 | 2024-05-15 |
4 | 2024-05-02 |
SC 13G | 2024-04-18 |
SC 13D/A | 2024-04-08 |
4 | 2024-03-28 |
3 | 2024-03-25 |
4 | 2024-03-25 |
4 | 2024-03-20 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.